Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa - Rabey, J M; Sagi, I; Huberman, M (Clin Neuropharmacol, 2000)
et al.